Last reviewed · How we verify
CYCLOPHOSPHAMIDE and FLUDARABIN
At a glance
| Generic name | CYCLOPHOSPHAMIDE and FLUDARABIN |
|---|---|
| Also known as | CYTOXAN |
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19 (PHASE1)
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (PHASE1, PHASE2)
- CAR-T Cell Therapy Targeting to CD19 for R/R ALL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYCLOPHOSPHAMIDE and FLUDARABIN CI brief — competitive landscape report
- CYCLOPHOSPHAMIDE and FLUDARABIN updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI